Obesity rather than neoadjuvant chemotherapy predicts steatohepatitis in patients with colorectal metastasis
- 5 February 2013
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 205 (6) , 685-690
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic ResistanceJournal of Clinical Oncology, 2010
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Solitary Colorectal Liver MetastasisArchives of Surgery, 2006
- Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal MetastasesAnnals of Surgery, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver MetastasesAnnals of Surgery, 2004
- Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal MetastasesAnnals of Surgery, 2002
- Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] MetastasesAnnals of Surgical Oncology, 2001
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgeryAnnals of Oncology, 1999